Currently going through routine maintenance. Thank you for your patience.
About Oncospire...CGI and Mayo Clinic launched a joint venture, OncoSpire Genomics. The objectives of this venture are to try to discover and validate biomarkers in specific hematologic and urogenital disorders utilizing next-generation sequencing with a possible expansion into other solid tumors, such as esophageal, head and neck, breast and lung cancers. Additionally, the joint venture entity would engage in biomarker discovery utilizing Mayo’s next-generation sequencing facility and the development of commercial products in the form of diagnostic products and services, as well as early stage therapeutic markers.
For more information please call Cancer Genetics, Incorporated at 201.528.9200